- Home
- TIGR vs IMCR Comparison
TIGR vs IMCR Comparison
Compare TIGR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TIGR | IMCR |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TIGR | IMCR |
|---|---|---|
| Price | $9.30 | $38.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.20 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 4.0M | 317.0K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 328.15 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $489,538,356.00 | $379,590,000.00 |
| Revenue This Year | $62.71 | $32.31 |
| Revenue Next Year | $6.55 | $10.50 |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | ★ 76.50 | 28.11 |
| 52 Week Low | $5.64 | $23.15 |
| 52 Week High | $13.55 | $40.72 |
Technical Indicators
Market Signals| Indicator | TIGR | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 56.29 |
| Support Level | $8.54 | $35.81 |
| Resistance Level | $8.91 | $40.53 |
| Average True Range (ATR) | 0.46 | 1.77 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 80.21 | 56.11 |
Price Performance
Historical ComparisonAbout TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.